Chiara Cremolini, MD, PhD, Assesses Panitumumab Plus Triplet vs Doublet Chemotherapy in RAS/BRAF Wild-Type Metastatic CRC
September 25, 2022

Chiara Cremolini, MD, PhD, discussed results from the phase 3 TRIPLETE study of triplet chemotherapy plus panitumumab in previously untreated patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer.

European Commission Approves Nivolumab/Relatlimab Combo for Treatment of Unresectable or Metastatic Melanoma
September 25, 2022

The European Commission based its approval of nivolumab/relatlimab for patients with a PD-L1 expression of less than 1% on the results of the phase 2/3 RELATIVITY-047 trial.

Recap: Efficacy and Safety of Seribantumab in NRG1 Fusion–Positive Cancers
September 24, 2022

One of the CRESTONE investigators, Tejas Patil, MD, assistant professor of medicine–medical oncology at the University of Colorado School of Medicine in Aurora, discussed seribantumab in previously treated patients with NRG1 fusion–positive tumors.

Catherine A. Shu, MD, Reviews Findings of Cohort A of the Phase 1 CHRYSALIS-2 Trial in Pretreated EGFR+ NSCLC
September 24, 2022

Catherine A. Shu, MD, spoke about the most important findings from the phase 1 CHRYSALIS-2 trial for patients with previously treated EGFR-mutant non–small cell lung cancer who are administered amivantamab plus lazertinib.

Amit Oza, MD, MBBS, FRCPC, Highlights the Benefit of Early Maintenance PARP Inhibitor Use in Ovarian Carcinoma
September 23, 2022

PARP inhibitors such as rucaparib appear to garner the most benefit in the early maintenance setting in patients with ovarian cancer who have less advanced disease and less heterogeneity, according to Amit Oza, MD, MBBS, FRCPC.

Doris K. Hansen, MD, Analyzes Real-World Experiences With Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma
September 23, 2022

Doris K. Hansen, MD, discussed results of an efficacy analysis examining the BCMA-directed CAR T-cell therapy idecabtagene vicleucel in real-world treatment of patients with relapsed/refractory multiple myeloma.

First-Line Olaparib/Bevacizumab Maintenance Combo Approved in China for HRD+ Advanced Ovarian Cancer
September 23, 2022

Olaparib and bevacizumab has been approved in China as a frontline maintenance treatment for patients with advanced homologous recombination deficiency–positive ovarian cancer based on results from the phase 3 PAOLA-1 and SOLO-1 trials.

Anne Chiang, MD, PhD, Studies Biomarkers for Immunotherapy Response in SCLC
September 23, 2022

Anne Chiang, MD, PhD, discussed results from a pilot study of biomarkers in tumors treated with ipilimumab and nivolumab in extensive-stage small cell lung cancer.

Improving Outcomes in Non-Small Cell Lung Cancer: Future Directions in Care
September 23, 2022

Best treatment approaches for patients with advanced NSCLC in the context of individualized therapy and an evolving therapeutic landscape.

Fred Saad, MD, FRCS, Highlights Positive OS Trend With Abiraterone and Olaparib in mCRPC But Cites Need for Longer Follow-up
September 22, 2022

Abiraterone and olaparib continued to demonstrate a positive trend in overall survival (OS) in patients with metastatic castration-resistant prostate cancer, according to Fred Saad, MD, FRCS, though he stated that longer follow-up is needed to confirm the benefit.